Expert Ratings for Vertex Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the last quarter, 18 analysts have provided ratings for Vertex Pharmaceuticals (NASDAQ:VRTX), with 4 being bullish, 8 somewhat bullish, and 6 indifferent. The company has an average 12-month price target of $371.11, with a high of $425.00 and a low of $315.00. This average price target has increased by 5.13% over the past month.
September 07, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts' ratings for Vertex Pharmaceuticals are mostly bullish or somewhat bullish, with an increasing 12-month price target, indicating a positive outlook for the company.
The majority of analysts have given bullish or somewhat bullish ratings for Vertex Pharmaceuticals, indicating a positive sentiment towards the company. Additionally, the average 12-month price target has increased over the past month, suggesting that analysts expect the company's stock price to rise in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100